Sana Biotechnology
Sana Biotechnology is a pioneering company focused on developing engineered cell therapies to treat and potentially cure a wide range of diseases. Their mission involves repairing and controlling genes in cells, replacing damaged cells, and making therapies broadly accessible. They are advancing innovative drug candidates targeting diseases like cancer, diabetes, and autoimmune disorders, with a strong emphasis on scientific discovery, patient-centric approaches, and scalable manufacturing.
Industries
Nr. of Employees
large (251-1000)
Sana Biotechnology
Products
Hypoimmune CAR T Cell Therapy
A treatment designed to avoid immune rejection and target cancer cells, using modified T cells from healthy donors.
In Vivo Cell Engineering
A platform aiming to modify genes within the body to treat diseases, focusing on delivery, gene modification, and execution.
Ex Vivo Cell Engineering
Cells are collected and modified outside the body to treat diseases, including autologous and allogeneic cell therapies.
SC291 (CD19) for Oncology
A hypoimmune allogeneic CD19-directed CAR T cell therapy in Phase 1 study for B-cell malignancies.
SC291 (CD19) for Autoimmune Diseases
A hypoimmune allogeneic CD19-directed CAR T cell therapy in Phase 1 study for severe B-cell mediated autoimmune diseases.
SC262 (CD22) T cells for Oncology
A hypoimmune allogeneic CD22-directed CAR T cell therapy in Phase 1 study for B-cell malignancies.
Hypoimmune CAR T Cell Therapy
A treatment designed to avoid immune rejection and target cancer cells, using modified T cells from healthy donors.
In Vivo Cell Engineering
A platform aiming to modify genes within the body to treat diseases, focusing on delivery, gene modification, and execution.
Ex Vivo Cell Engineering
Cells are collected and modified outside the body to treat diseases, including autologous and allogeneic cell therapies.
SC291 (CD19) for Oncology
A hypoimmune allogeneic CD19-directed CAR T cell therapy in Phase 1 study for B-cell malignancies.
SC291 (CD19) for Autoimmune Diseases
A hypoimmune allogeneic CD19-directed CAR T cell therapy in Phase 1 study for severe B-cell mediated autoimmune diseases.
SC262 (CD22) T cells for Oncology
A hypoimmune allogeneic CD22-directed CAR T cell therapy in Phase 1 study for B-cell malignancies.